The global aortic stents grafts market size was estimated to be USD 2.84 billion in 2023 and is expected to reach at USD 5.10 billion by 2034 with a CAGR of 5.46% during the forecast period 2024-2034. Rising prevalence of cardiovascular disorders, growing demand for minimally invasive surgeries, increasing demand for minimally invasive surgical procedures, surge in number of screening procedures for early detection, rising popularity of endovascular repair, growing clinical trial procedures, surge in awareness regarding minimally invasive endovascular aneurysm repair procedures, and increasing regulatory approvals for stent grafts are some of the key factors boosting the market growth.
Increasing regulatory approvals for stent grafts is predicted to boost the market growth during the forecast period. Patients' preference for less invasive operations is growing, which increases the need for minimally invasive equipment. For instance, in April 2022, Terumo Aortic has initiated patient enrollment in a comprehensive study for Abdominal Aortic Aneurysm (AAA) utilizing the TREO Abdominal Stent-Graft System in the United States. The FDA has granted approval for the use of the TREO abdominal stent-graft system in the treatment of individuals with abdominal aortic aneurysms.
By product, abdominal aortic stent graft was the highest revenue-grossing segment in the global aortic stents grafts market in 2023 owing to increasing awareness regarding effectiveness & benefits of EVAR using stent grafts compared to open surgery and rising approvals from regulatory bodies. For instance, in August 2022, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. has obtained registration approval for the Minos Abdominal Aortic Stent-Graft and Delivery System from the Colombian National Institute for Drug and Food Surveillance (INVIMA). Colombia now becomes the third Latin American country, following Brazil and Argentina, to introduce the Minos System. Additionally, thoracic aortic stent graft is predicted to grow at fastest CAGR during the forecast period owing to the growing regulatory approvals of thoracic aortic stent graft and surge in technological advancements.
By end-user, hospitals was the highest revenue-grossing segment in the global aortic stents grafts market in 2023 owing to the rising aortic aneurysm repair procedures for both abdominal & thoracic aortic aneurysms performed in hospitals, increasing prevalence of aortic aneurysms, surge in hospitalization for diagnosis, monitoring, & treatment, and growing collaborations within market players. For instance, in September 2022, Getinge has entered into a supply arrangement with Medtronic, following Medtronic's recent acquisition of the CE mark for the Radiant covered stent. This stent is notably the first one designed for chimney endovascular aneurysm repair (ChEVAR). The Radiant covered stent is a Getinge-manufactured Advanta V12 balloon expandable covered stent, distributed under the Medtronic label. Additionally, ambulatory surgical centers (ASCs) is predicted to grow at fastest CAGR during the forecast period owing to the ASCs provide patients with flexible scheduling choices so they may pick the day and time of their surgery and growing adoption of cutting-edge technologies.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for minimally invasive surgery, growing prevalence of cardiovascular disorders, obesity, rising advanced healthcare systems, and surge in approvals by regulatory bodies. For instance, in August 2022, Endologix LLC., a privately held worldwide medical device firm, announced that their AFX2 Endovascular AAA System has gained CE Mark Certification under the new EU Medical Devices Regulation. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of obesity & aortic aneurysm, rising technological advancements in the aortic stent graft devices, and growing approvals by regulatory bodies. For instance, in March 2022, RelayBranch Thoracic Stent-Graft System obtained Breakthrough Device Designation from the US Food and Drug Administration (FDA), according to Terumo Aortic's announcement. Patients with disorders of the thoracic aortic arch who require therapy involving coverage of the innominate and left common carotid arteries are treated using the RelayBranch Thoracic Stent-Graft System.
Increasing regulatory approvals for stent grafts is predicted to boost the market growth during the forecast period. Patients' preference for less invasive operations is growing, which increases the need for minimally invasive equipment. For instance, in April 2022, Terumo Aortic has initiated patient enrollment in a comprehensive study for Abdominal Aortic Aneurysm (AAA) utilizing the TREO Abdominal Stent-Graft System in the United States. The FDA has granted approval for the use of the TREO abdominal stent-graft system in the treatment of individuals with abdominal aortic aneurysms.
By product, abdominal aortic stent graft was the highest revenue-grossing segment in the global aortic stents grafts market in 2023 owing to increasing awareness regarding effectiveness & benefits of EVAR using stent grafts compared to open surgery and rising approvals from regulatory bodies. For instance, in August 2022, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. has obtained registration approval for the Minos Abdominal Aortic Stent-Graft and Delivery System from the Colombian National Institute for Drug and Food Surveillance (INVIMA). Colombia now becomes the third Latin American country, following Brazil and Argentina, to introduce the Minos System. Additionally, thoracic aortic stent graft is predicted to grow at fastest CAGR during the forecast period owing to the growing regulatory approvals of thoracic aortic stent graft and surge in technological advancements.
By end-user, hospitals was the highest revenue-grossing segment in the global aortic stents grafts market in 2023 owing to the rising aortic aneurysm repair procedures for both abdominal & thoracic aortic aneurysms performed in hospitals, increasing prevalence of aortic aneurysms, surge in hospitalization for diagnosis, monitoring, & treatment, and growing collaborations within market players. For instance, in September 2022, Getinge has entered into a supply arrangement with Medtronic, following Medtronic's recent acquisition of the CE mark for the Radiant covered stent. This stent is notably the first one designed for chimney endovascular aneurysm repair (ChEVAR). The Radiant covered stent is a Getinge-manufactured Advanta V12 balloon expandable covered stent, distributed under the Medtronic label. Additionally, ambulatory surgical centers (ASCs) is predicted to grow at fastest CAGR during the forecast period owing to the ASCs provide patients with flexible scheduling choices so they may pick the day and time of their surgery and growing adoption of cutting-edge technologies.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for minimally invasive surgery, growing prevalence of cardiovascular disorders, obesity, rising advanced healthcare systems, and surge in approvals by regulatory bodies. For instance, in August 2022, Endologix LLC., a privately held worldwide medical device firm, announced that their AFX2 Endovascular AAA System has gained CE Mark Certification under the new EU Medical Devices Regulation. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of obesity & aortic aneurysm, rising technological advancements in the aortic stent graft devices, and growing approvals by regulatory bodies. For instance, in March 2022, RelayBranch Thoracic Stent-Graft System obtained Breakthrough Device Designation from the US Food and Drug Administration (FDA), according to Terumo Aortic's announcement. Patients with disorders of the thoracic aortic arch who require therapy involving coverage of the innominate and left common carotid arteries are treated using the RelayBranch Thoracic Stent-Graft System.
Segmentation: Aortic Stents Grafts Market Report 2022 - 2033
Aortic Stents Grafts Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Thoracic Aortic Stent Graft
- Abdominal Aortic Stents Graft
Aortic Stents Grafts Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Hospitals
- Specialty Clinics
Aortic Stents Grafts Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Aortic Stents Grafts Market: Product Estimates & Trend Analysis
8. Aortic Stents Grafts Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Aortic Stents Grafts Market
11. Europe Global Aortic Stents Grafts Market
12. Asia Pacific Global Aortic Stents Grafts Market
13. Latin America Global Aortic Stents Grafts Market
14. MEA Global Aortic Stents Grafts Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Terumo Corporation Inc
- Cook Medical Inc
- Medtronic Plc
- Cryolife Inc
- Lombard Medical Inc
- Cardinal Health Inc
- Endologix Inc
- Becton
- Dickinsn and Company
- MicroPort Scientific Corporation Inc
- Lifetech Scientific
- Cordis
- W.L. Gore & Associates
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.84 Billion |
| Forecasted Market Value ( USD | $ 5.1 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
